Biotech Axoltis pharma Launches Funding Drive for Promising ALS treatment
Lyon, France - October 8, 2024 – French biotech firm Axoltis Pharma today announced a public fundraising campaign to accelerate the progress of NX210C, a novel treatment currently in late-stage clinical trials for Amyotrophic Lateral Sclerosis (ALS), also known as Charcot’s disease. The move offers the public an possibility to invest in a potential breakthrough for a disease with limited therapeutic options.
ALS is a progressive neurodegenerative disease affecting motor neurons, leading to muscle weakness, paralysis, and ultimately, death. Currently, treatments focus on managing symptoms and slowing disease progression, offering only modest benefits. axoltis Pharma believes NX210C represents “a new therapeutic outlook and hope for patients,” aiming to provide a more effective response where current approaches fall short, according to Chairman of the Biotech Management Board, Yann Godfrin.
clinical trials, led by Dr. Émilien Bernard of the Reference Center Rare Diseases of Civil Hospices in Lyon, are nearing completion of phase 2, involving 80 patients. Preliminary data from a phase 1B study in 2023 indicated a “good profile of tolerance” for NX210C, according to Axoltis Pharma.Phase 2 results evaluating the drug’s effectiveness are expected by April 2026, followed by two further phases to confirm therapeutic benefits and conduct a large-scale assessment.
the fundraising campaign, hosted on the Capital Cell platform, is open until the end of october and seeks to accelerate the drug’s development. ”With NX210C, we have the ambition to provide a therapeutic response where there are only very modestly effective approaches today,” Godfrin stated. “Opening our capital to the general public is allowing everyone to take part in the clinical development of an innovative and very promising drug for the treatment of neurodegenerative diseases such as ALS.”
